CO5210862A1 - Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia - Google Patents

Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia

Info

Publication number
CO5210862A1
CO5210862A1 CO00069700A CO00069700A CO5210862A1 CO 5210862 A1 CO5210862 A1 CO 5210862A1 CO 00069700 A CO00069700 A CO 00069700A CO 00069700 A CO00069700 A CO 00069700A CO 5210862 A1 CO5210862 A1 CO 5210862A1
Authority
CO
Colombia
Prior art keywords
reboxetine
dosage
day
methods
effective therapy
Prior art date
Application number
CO00069700A
Other languages
English (en)
Inventor
Sylvia Seroff
Yam Noymi
D Ayer Atul
Bhatt Padmanabh
Michael A Desjardin
Phillip R Nixon
Edgren David Emil
Andrew C Lam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CO5210862A1 publication Critical patent/CO5210862A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una forma de dosificación de liberación sostenida adaptada para la liberación de reboxetina a un índice uniforme, durante un período de tiempo prolongado.La forma de dosificación de la reivindicación 1, en donde la forma de dosificación de liberación sostenida es una composición osmótica que comprende un componente que contiene reboxetina en mezcla con un agente osmótico dentro de un compartimiento interno; dicho compartimiento interno es definido por una membrana semipermeable a través de la cual se suministra reboxetina por medio de un orificio de suministro formado, o capaz de ser formado, en dicha membrana semipermeable.<EMI FILE="00069700_1" ID="1" IMF=JPEG >
CO00069700A 1999-09-15 2000-09-14 Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia CO5210862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15399799P 1999-09-15 1999-09-15

Publications (1)

Publication Number Publication Date
CO5210862A1 true CO5210862A1 (es) 2002-10-30

Family

ID=22549601

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00069700A CO5210862A1 (es) 1999-09-15 2000-09-14 Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia

Country Status (13)

Country Link
US (2) US6387403B1 (es)
EP (1) EP1216031B1 (es)
JP (1) JP2003509354A (es)
KR (2) KR100831181B1 (es)
AR (1) AR031978A1 (es)
AT (1) ATE356619T1 (es)
AU (1) AU7490700A (es)
CA (1) CA2384624C (es)
CO (1) CO5210862A1 (es)
DE (1) DE60033947T2 (es)
PE (1) PE20010625A1 (es)
TW (1) TWI233809B (es)
WO (1) WO2001019337A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
EP1503732B1 (en) * 2002-04-29 2008-10-08 Alza Corporation Reduced formate poly(alkylene oxides) with reboxetine for reducing impurity formation
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
CA2524300C (en) * 2003-08-08 2008-10-28 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
KR101169614B1 (ko) * 2003-09-26 2012-08-03 알자 코포레이션 상승한 방출 속도를 나타내는 제어 방출 제제
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
PT1789021E (pt) 2004-08-13 2011-12-22 Boehringer Ingelheim Int Formulação de comprimidos de libertação prolongada contendo pramipexole ou um seu sal farmaceuticamente aceitável
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
PT2168585E (pt) * 2005-06-09 2012-03-05 Euro Celtique Sa Composições farmacêuticas de um esteróide neuroactivo e as suas utilizações
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8088786B2 (en) * 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US10485770B2 (en) * 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
US9937335B2 (en) * 2011-06-06 2018-04-10 Oak Crest Institute Of Science Drug delivery device employing wicking release window
ES2924024T3 (es) 2012-06-06 2022-10-04 Nalpropion Pharmaceuticals Llc Composición para su uso en un método para el tratamiento del sobrepeso y la obesidad en pacientes con alto riesgo cardiovascular
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
CN111077238A (zh) * 2019-11-12 2020-04-28 北京和合医学诊断技术股份有限公司 检测血液中瑞波西汀药物含量液相色谱分析方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4384005A (en) * 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
RU2120798C1 (ru) * 1991-11-22 1998-10-27 Проктер энд Гэмбл Фармасьютикалз, Инк. Твердая фармацевтическая композиция для перорального введения
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
EP0714411B1 (en) 1994-06-16 1999-07-21 PHARMACIA &amp; UPJOHN S.p.A. Process for obtaining mucoadhesive starch
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
CA2306233A1 (en) 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals

Also Published As

Publication number Publication date
KR100723850B1 (ko) 2007-05-31
CA2384624C (en) 2009-12-29
KR100831181B1 (ko) 2008-05-21
US20020146453A1 (en) 2002-10-10
EP1216031B1 (en) 2007-03-14
EP1216031A2 (en) 2002-06-26
DE60033947D1 (de) 2007-04-26
DE60033947T2 (de) 2007-11-29
KR20070007215A (ko) 2007-01-12
ATE356619T1 (de) 2007-04-15
US6387403B1 (en) 2002-05-14
JP2003509354A (ja) 2003-03-11
AU7490700A (en) 2001-04-17
AR031978A1 (es) 2003-10-22
PE20010625A1 (es) 2001-06-04
US6630165B2 (en) 2003-10-07
WO2001019337A3 (en) 2001-08-09
KR20020031424A (ko) 2002-05-01
CA2384624A1 (en) 2001-03-22
TWI233809B (en) 2005-06-11
WO2001019337A2 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
CO5210862A1 (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
DE60118395D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung für die parenterale applikation von hydrophilen wirkstoffen
CR11283A (es) &#34;composicion de liberacion sostenida y proceso para producirla&#34;
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
ECSP034455A (es) Forma de dosificacion de farmaco activada por hidrogel
GT200400242A (es) Uso extendido de combinacion que comprende estrogenos y progestina.
MY135711A (en) Osmotic delivery system with early zero order push power engine
PE88699A1 (es) Formas de dosificacion de liberacion sostenida de sertralina
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
AU2001246458A1 (en) Skin cleansing gel having a heating effect
ECSP045451A (es) Metodos y formas de dosificacion para la entrega controlada de oxicodona
AR021858A1 (es) Composicion de liberacion modificada de particulas multiples
BR0107549A (pt) Composição de pró-perfume
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
PT1091747E (pt) Utilizacao de solucoes salinas isotermicas para a prevencao de inflamacoes
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
AR241747A1 (es) Dispositivo de bolo de liberacion controlada.
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
FI972004A0 (fi) Implantoitava laite vaikuttavien aineiden antamiseen kasveille
BRPI0415232A (pt) uso de xenÈnio com hipotermia para tratar asfixia neonatal
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion

Legal Events

Date Code Title Description
FC Application refused